943 degrees, 13 PhDs, 21 gold medals given at Mahindra University convocation
While learning for growth and making an impact, he encouraged the students to build communities and work places that break barriers and promote innovation.
The fourth convocation of Mahindra University saw degrees awarded to 943 students from engineering, management, law, and education disciplines, and 13 Ph.Ds. Besides, 21 students were awarded gold medals for meritorious academic performance. It was the first convocation for students of MBA, LLB, MA, and B. Tech nanotechnology programmes.
University Chancellor Anand Mahindra called upon students to not only embody the values of compassion, critical thinking, and ethics, but also take ownership as architects of a brighter future. He urged them to live by their values and shape a world rooted in sustainability, inclusivity, and justice.
CEO and MD of Tech Mahindra, and Board Member Mohit Joshi stressed on the need for professionals who can bridge disciplines, question the status quo, and innovate with purpose. He said the university will thrive on partnerships across industries.
Mr. Prasad, Mr. Mahindra, Mr. Joshi, and Vice-Chancellor Yajulu Medury inaugurated the new biotechnology labs. On Saturday, Mr. Mahindra inaugurated the centre for risk management.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
04-08-2025
- Hans India
Mahindra University commends 956 Graduates at Fourth Convocation
Hyderabad: Mahindra University recently held its fourth annual convocation, celebrating the achievements of 956 students at its Bahadurpally campus. The graduating class included 943 students from its engineering, management, law, and education schools, as well as 13 PhD scholars. The ceremony was attended by proud parents, faculty, and special guests. The event's Chief Guest was G V Prasad, Co-Chairman and Managing Director of Dr Reddy's Laboratories. The ceremony was presided over by Mahindra University Chancellor, Anand Mahindra, and attended by other dignitaries including Mohit Joshi, a Member of the Board of Management, Mahindra University, and CEO & MD, Tech Mahindra, and the university's Vice Chancellor, Dr YajuluMedury. In his address, Prasad encouraged the graduates to be collaborative, highlighting the need to build communities and workplaces that foster innovation. He urged them to embrace lifelong learning and believe in their ability to overcome self-limiting beliefs. Anand Mahindra's speech emphasised the university's mission to educate 'citizens for and of a better world'. He called on the graduates to act as both inheritors and architects of the future, living by their values and shaping a world rooted in sustainability, inclusivity, and justice. This convocation was a particularly significant milestone as it marked the first graduating class for several new programmes, including the Master of Business Administration (MBA), Bachelor of Laws (LLB), Master of Arts (MA), and Bachelor of Technology (B. Tech) Nanotechnology. Mohit Joshi spoke about the importance of professionals who can bridge disciplines and innovate with purpose. He also noted the growing partnership between the university and industry, with Tech Mahindra playing a key role in this ecosystem. Earlier in the day, G V Prasad and Anand Mahindra inaugurated new biotechnology labs, while Mahindra had opened the Centre for Risk Management on Saturday. These new initiatives underscore the university's dedication to research and innovation.
The Hindu
03-08-2025
- The Hindu
943 degrees, 13 PhDs, 21 gold medals given at Mahindra University convocation
Build a mosaic of experiences, collaborate like flocking birds which learn together and thrive, and believe in the ability to overcome self-limiting beliefs, Co-Chairman and Managing Director of Dr Reddy's Laboratories G.V. Prasad told graduating students at Mahindra University here on Sunday. While learning for growth and making an impact, he encouraged the students to build communities and work places that break barriers and promote innovation. The fourth convocation of Mahindra University saw degrees awarded to 943 students from engineering, management, law, and education disciplines, and 13 Besides, 21 students were awarded gold medals for meritorious academic performance. It was the first convocation for students of MBA, LLB, MA, and B. Tech nanotechnology programmes. University Chancellor Anand Mahindra called upon students to not only embody the values of compassion, critical thinking, and ethics, but also take ownership as architects of a brighter future. He urged them to live by their values and shape a world rooted in sustainability, inclusivity, and justice. CEO and MD of Tech Mahindra, and Board Member Mohit Joshi stressed on the need for professionals who can bridge disciplines, question the status quo, and innovate with purpose. He said the university will thrive on partnerships across industries. Mr. Prasad, Mr. Mahindra, Mr. Joshi, and Vice-Chancellor Yajulu Medury inaugurated the new biotechnology labs. On Saturday, Mr. Mahindra inaugurated the centre for risk management.
Time of India
05-06-2025
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
